A Randomized Phase II Study to Evaluate Efficacy of T-DM1 With or Without Palbociclib in the Treatment of Patients With Metastatic HER2 Positive Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2019
Price : $35 *
At a glance
- Drugs Palbociclib (Primary) ; Trastuzumab emtansine (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 20 Dec 2018 Status changed from not yet recruiting to recruiting.
- 06 Nov 2018 Planned initiation date changed from 30 Sep 2018 to 30 Nov 2018.
- 06 Sep 2018 Planned End Date changed from 31 Aug 2023 to 1 Aug 2022.